Regulatory aspects of drug development in Europe

Description. The One Health approach recognizes the interconnectedness of human, animal, and environmental health, aiming to address planetary health issues, including parasitic diseases, through an holistic and collaborative approach. When it comes to drug development for Parasitic Vector-Borne Diseases (PVBDs), there are several regulatory aspects that should be analyzed under the One Health framework for an effective multidisciplinary collaboration, targeting sustainability of drug development, its production and distribution.  Therefore, to meet the One Health approach expectations for drug development against PVBDs, careful consideration of regulatory aspects that encompass human and animal health, ethical concerns, environmental impact, and international collaboration mut be considered. Effective communication and coordination among regulatory agencies, researchers, and stakeholders are essential to bring safe and effective drugs to both humans and animals.

At “Regulatory aspects of drug development” we aim at enlightening COST Action 21111 audience and partners on some fundamental aspects for Drug Development Regulations in Europe, and how they imply in the drug development and distribution of drugs for human and animal PVBD. 

-------------

For registration to the meeting please find below the information:

For non-COST members, registration requires two steps : 

1) create an e-COST account at www.cost.eu  

2) register here: https://docs.google.com/forms/d/e/1FAIpQLScDI1TzZO6kRmn5916-dtVQUzusuxcGkc_dclCxIMpdfpiaBA/viewform?usp=sharing by the 7/10/2023